> KV Pharmaceuticals has expanded its partnership Acrux, which developed a spray technology that is used in Evamist, KV's hot flash remedy. Report
> A GlaxoSmithKline executive, Steve Stefano, is hoping to generate big buzz for his new book on leadership, saying that "integrity, courage, empathy, passion are the values and behaviors of true leaders." Report
> CVS Caremark will take over more of the West when it spends $2.7 billion and assume all debts for Longs drugstores. Report
> Are Schering-Plough and Pfizer enjoying the dragging U.S. economy more than other pharma companies because they sell more overseas? Report
> The FDA has accepted a NDA and granted priority review for Remoxy, a controlled-release oxycodone chronic pain reliever that Pain Therapeutics and King Pharmaceuticals say is abuse-resistant for patients with moderate to severe chronic pain. Report
> The "godfather" of the UK's biotech industry has a dose of bitter news for his colleagues in drug development. Report
> Hitting a primary endpoint in a late-stage trial is not always a recipe for success, it seems. Shares of Altus Pharmaceuticals nosedived this morning after the company issued a release saying that its late-stage study of the cystic fibrosis drug Trizytek hit its primary endpoint in fat absorption. Report
> Is Carl Icahn girding for a renewed war with Biogen Idec's management team? Report
> Life science VC firm InterWest Partners has closed a $650 million fund. Report
> Just seven months after raising $5.5 million in its Series A round, Boston-based Follica announced that it has raised $11 million more in a Series B. Report
And Finally... If you want to find drugs, check out the bright bugs: A new study says rainforest insects with vivid colors enjoy relaxing on medicinally-active plants. Report